Payment overview · 2025
General Payments
$173.99
9 reported records · 5 companies
Healthcare provider profile · identity verified
Mark W. Lefler, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HOT SPRINGS, AR · NPI 1255310819
Verified facts
What the public records show
CMS Open Payments records show Mark W. Lefler, M.D. received $173.99 in general payments during 2025 across 9 reported records.
ABBVIE INC. accounted for 32.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.12 | 32.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.95 | 20.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.78 | 17.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.68 | 17.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.46 | 13.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $173.99 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $56.12 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $29.78 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.68 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.68 | 2 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $23.46 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 138 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
138 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 551 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 521 | 125 |
| Pantoprazole Sodium | Pantoprazole Sodium | 412 | 106 |
| Lisinopril | Lisinopril | 329 | 92 |
| Potassium Chloride | Potassium Chloride | 313 | 68 |
| Pravastatin Sodium | Pravastatin Sodium | 300 | 81 |
| Gabapentin | Gabapentin | 296 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 279 | 78 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 246 | 39 |
| Meloxicam | Meloxicam | 238 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 228 | 59 |
| Furosemide | Furosemide | 222 | 45 |
| Valsartan | Valsartan | 204 | 42 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 202 | 59 |
| Omeprazole | Omeprazole | 191 | 53 |
| Famotidine | Famotidine | 187 | 46 |
| Simvastatin | Simvastatin | 183 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 174 | 47 |
| Sertraline Hcl | Sertraline Hcl | 172 | 35 |
| Losartan Potassium | Losartan Potassium | 166 | 45 |
| Metformin Hcl | Metformin Hcl | 161 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 155 | 29 |
| Methylprednisolone | Methylprednisolone | 153 | 115 |
| Trazodone Hcl | Trazodone Hcl | 148 | 33 |
| Ozempic | Semaglutide | 138 | 19 |
| Tramadol Hcl | Tramadol Hcl | 136 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 42 |
| Allopurinol | Allopurinol | 123 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 20 |
| Eliquis | Apixaban | 106 | 21 |
| Azithromycin | Azithromycin | 104 | 87 |
| Oxybutynin Chloride | Oxybutynin Chloride | 102 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 97 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 27 |
| Clonazepam | Clonazepam | 91 | 11 |
| Glimepiride | Glimepiride | 91 | 21 |
| Mirtazapine | Mirtazapine | 90 | 16 |
| Donepezil Hcl | Donepezil Hcl | 89 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 89 | 75 |
| Carvedilol | Carvedilol | 87 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 19 |
| Montelukast Sodium | Montelukast Sodium | 84 | 18 |
| Alprazolam | Alprazolam | 83 | 20 |
| Bupropion Xl | Bupropion Hcl | 83 | 22 |
| Temazepam | Temazepam | 83 | 18 |
| Jardiance | Empagliflozin | 80 | 12 |
| Memantine Hcl | Memantine Hcl | 80 | 13 |
| Buspirone Hcl | Buspirone Hcl | 77 | 17 |
| Ezetimibe | Ezetimibe | 69 | 17 |
| Spironolactone | Spironolactone | 68 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 63 | 20 |
| Ramipril | Ramipril | 63 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 57 | 23 |
| Primidone | Primidone | 56 | 13 |
| Synthroid | Levothyroxine Sodium | 56 | 14 |
| Finasteride | Finasteride | 53 | 13 |
| Pregabalin | Pregabalin | 51 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 49 | suppressed |
| Diazepam | Diazepam | 47 | 11 |
| Fenofibrate | Fenofibrate | 47 | suppressed |
| Lorazepam | Lorazepam | 47 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 13 |
| Valacyclovir | Valacyclovir Hcl | 47 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 36 |
| Estradiol | Estradiol | 43 | 11 |
| Meclizine Hcl | Meclizine Hcl | 43 | 20 |
| Metformin Hcl Er | Metformin Hcl | 42 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 40 | 40 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Prednisone | Prednisone | 37 | suppressed |
| Sucralfate | Sucralfate | 37 | 15 |
| Cephalexin | Cephalexin | 36 | 34 |
| Atenolol | Atenolol | 35 | suppressed |
| Celecoxib | Celecoxib | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | 22 |
| Klor-Con M20 | Potassium Chloride | 33 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 18 |
| Irbesartan | Irbesartan | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 16 |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Itraconazole | Itraconazole | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 19 | suppressed |
| Indapamide | Indapamide | 19 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 16 |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $173.99 · 9 records | ABBVIE INC. | CARDIOMEMS, KISUNLA, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error